Exodus Point Capital Management, LP Relmada Therapeutics, Inc. Transaction History
Exodus Point Capital Management, LP
- $16.4 Billion
- Q3 2024
A detailed history of Exodus Point Capital Management, LP transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 68,000 shares of RLMD stock, worth $204,680. This represents 0.0% of its overall portfolio holdings.
Number of Shares
68,000Holding current value
$204,680% of portfolio
0.0%Shares
6 transactions
Others Institutions Holding RLMD
# of Institutions
81Shares Held
12.3MCall Options Held
229KPut Options Held
138K-
Franklin Resources Inc San Mateo, CA1.3MShares$3.92 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.26MShares$3.78 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.19MShares$3.57 Million0.01% of portfolio
-
Parsons Capital Management Inc1MShares$3.02 Million0.21% of portfolio
-
Palo Alto Investors LP Palo Alto, CA732KShares$2.2 Million0.33% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $86.1M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...